Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk
Authors:
- A AndoAAA Ando
- S HasegawaSHS Hasegawa
- M IshitobiMIM Ishitobi
- J YamamuraJYJ Yamamura
- N IraharaNIN Irahara
- Y TanjiYTY Tanji
- T TaguchiTTT Taguchi
- Y TamakiYTY Tamaki
- S NoguchiSNS Noguchi
- 1 November 2003
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (17) , 2531-2537
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 16 references indexed in Scilit:
- Breast Cancer Risk Associated with CYP1A1 Genetic Polymorphisms in Japanese WomenThe Breast Journal, 2002
- Breast cancer risk associated with polymorphism inCYP19 in Japanese womenInternational Journal of Cancer, 2000
- Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolismMutation Research - Reviews in Mutation Research, 2000
- The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancerBreast Cancer Research and Treatment, 1999
- Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast CancerJNCI: Journal of the National Cancer Institute, 1999
- Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in TaiwanBritish Journal of Cancer, 1999
- Role of Estradiol Metabolism and CYP1A1 Polymorphisms in Breast Cancer RiskCancer Detection Prevention, 1999
- Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer riskBritish Journal of Cancer, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- A rare CYP19 (aromatase) variant may increase the risk of breast cancerPharmacogenetics, 1998